Fibrocell Science, Inc. is an aesthetic and therapeutic development stage biotechnology company focused on developing skin and tissue rejuvenation products. The Company�s clinical development product candidates are designed to improve the appearance of skin injured by the effects of aging, sun exposure, acne and burn scars with a patient�s own, or autologous, fibroblast cells produced by its Fibrocell process. The Company�s clinical development programs encompass both aesthetic and therapeutic indications. Through December 31, 2011, the Company has been primarily engaged in developing its initial product technology. Its lead product, LAVIV (United States adopted name, or USAN, is azficel-T), is the personalized aesthetic cell therapy approved by the Food and Drug Administration (FDA). LAVIV offers patients their own living fibroblast cells in a personalized therapy designed to improve the appearance of wrinkles.